

---

Corrigendum

## **Corrigendum to: Subgroup analysis of Japanese patients in a Phase 3 study of atezolizumab in advanced triple-negative breast cancer (IMpassion130)**

**Hiroji Iwata<sup>1,\*</sup>, Kenichi Inoue<sup>2</sup>, Koji Kaneko<sup>3</sup>, Yoshinori Ito<sup>4</sup>, Koichiro Tsugawa<sup>5</sup>, Ayumi Hasegawa<sup>6</sup>, Shintaro Nakagawa<sup>6</sup>, Hiroyasu Kuratomi<sup>6</sup>, and Kenji Tamura<sup>7</sup>**

---

Japanese Journal of Clinical Oncology, hyz135, <https://doi.org/10.1093/jjco/hyz135>

In the originally approved version of this article, Figures 1(A) and 1(B) were misplaced and thus labelled to incorrectly represent the opposite dataset. Figure 1(A) represented PD-L1-positive patients. Figure 1(B) represented progression-free survival in Japanese patients. The figures have now been placed in their correct locations and are accurately labelled. Figure 1(A) now correctly represents progression-free survival in Japanese patients. Figure 1(B) now correctly represents PD-L1-positive patients.